Chalice Medical, a UK-based manufacturer specializing in extracorporeal life support (ECLS) solutions, is proud to announce the launch of its U.S. distribution arm, Chalice Medical Inc. This strategic expansion brings Chalice’s industry-leading devices to the U.S. market, led by the CMO8 Oxygenator.
Founded in 1998, Chalice Medical Ltd has established itself as a trusted provider of high-quality solutions for cardiac and perfusion procedures. Their first oxygenator “The Paragon” was launched in 2011 and has grown to include patient demographics ranging from adults to neonates. With a commitment to innovation, quality, and patient care, the company manufactures tens of thousands of oxygenators each year at its Nottinghamshire facility. Its products are exported to over 30 countries through a network of authorized distributors.
During the Covid-19 crisis, Chalice Medical rapidly scaled production to meet the increased demand for extracorporeal membrane oxygenation (ECMO) devices, supporting critical care units worldwide. The team’s swift response helped hospitals care for thousands of vulnerable patients. This challenging period not only strengthened their production capabilities but also reinforced their commitment to remaining at the forefront of patient care during any crisis.
The introduction of Chalice Medical Inc. marks a significant milestone in the company’s global growth. Chalice Medical Inc. will serve as a distributor, bringing Chalice Medical’s latest product, the new CMO8 Oxygenator, as well as the Parallel Simulator, a portable and customizable training system, to the U.S. market. The CMO8 stands out with its advanced features such as a large surface area, innovative flow path, and exceptional air handling capabilities, offering optimized gas transfer efficiency for critical care patients.
For more information on Chalice Medical Inc. and its products, visit https://www.chalice-inc.com/ or contact U.S. Commercial Leader, Bill Sevilla at bsevilla@chalicemedical.com.
